Emotional Dysregulation in Adult ADHD and Response to Atomoxetine

  title={Emotional Dysregulation in Adult ADHD and Response to Atomoxetine},
  author={Frederick W. Reimherr and Barrie K. Marchant and Robert E. Strong and Dawson W. Hedges and Lenard A Adler and Thomas J. Spencer and Scott A. West and Poonam Soni},
  journal={Biological Psychiatry},
Types of Adult Attention-Deficit/Hyperactivity Disorder: A Replication Analysis.
Factor analytic results supported the validity of 2 adult ADHD presentations based on levels of emotional dysregulation, and this system offers a more clinically relevant approach to the diagnosis of ADHD in adults than does the DSM system.
Emotional Lability in Patients with Attention-Deficit/Hyperactivity Disorder: Impact of Pharmacotherapy
Emotional lability (EL) symptoms are associated with more severe ADHD and co-morbidities, have significant impact on functioning, and may respond to treatment with medications frequently used to treat ADHD.
Types of adult attention-deficit hyperactivity disorder (ADHD): baseline characteristics, initial response, and long-term response to treatment with methylphenidate
Impairment and comorbidity in adults with ADHD are largely concentrated in ADHD emotional dysregulation presentation patients, which can be conceptualized as two types of ADHD in adults.
Is emotional dysregulation part of the psychopathology of ADHD in adults
Attention-deficit hyperactivity disorder is a common condition in adulthood. The disorder is charac- terized by symptoms of inattention, hyperactivity, and impulsivity. Alongside these symptoms, it
Emotional dysregulation in adult ADHD: what is the empirical evidence?
There is growing evidence that emotional dysregulation might be recognized as a core feature of ADHD, and pharmacological and psychotherapeutic interventions help to ameliorate emotional Dysregulation together with symptoms of inattention and hyperactivity/impulsivity.
Affect modulation of methylphenidate in patients with Attention Deficit Hyperactivity Disorder
The results support both a genetic and early developmental explanation of depressive comorbidity in ADHD and could be reassuring to therapists, parents and clients who are deciding on the use of stimulant medication for ADHD.
Emotion dysregulation in adults with attention deficit hyperactivity disorder: a meta-analysis
The findings support ED symptoms as a core feature of ADHD’s psychopathology and suggest that emotional lability, negative emotional responses, and emotion recognition play a more definitive role in the psychopathology of adults with ADHD.
Emotional dysregulation subgroups in patients with adult Attention-Deficit/Hyperactivity Disorder (ADHD): a cluster analytic approach
Emotion regulation deficits (ERD) are evident in about 34–70% of the adults with ADHD. In contrast to this, they are not considered in the diagnostic criteria of the disorder. In a recent study of
Six months methylphenidate treatment improves emotion dysregulation in adolescents with attention deficit/hyperactivity disorder: a prospective study
Purpose Individuals with attention deficit/hyperactivity disorder (ADHD) may suffer from emotional dysregulation (ED), although this symptom is not listed among the diagnostic criteria.


Attention-deficit/hyperactivity disorder in adults: an overview
A controlled study of Methylphenidate in the treatment of Attention Deficit Disorder, Residual Type, in Adults
The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability, and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders.
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.
Anxiety as a Predictor and Outcome Variable in the Multimodal Treatment Study of Children with ADHD (MTA)
Initial moderator analyses in the Multimodal Treatment Study of Children with ADHD (MTA) suggested that child anxiety ascertained by parent report on the Diagnostic Interview Schedule for Children
ADHD comorbidity findings from the MTA study: comparing comorbid subgroups.
Three clinical profiles are indicated, ADHD co-occurring with internalizing disorders (principally parent-reported anxiety disorders) absent any concurrent disruptive disorder (ADHD + ANX), ADHD Co-occurred with ODD/CD but no anxiety (AD HD + ODD /CD), and ADHD with both anxiety and O DD/CD may be sufficiently distinct to warrant classification as ADHD subtypes different from "pure" ADHD with neither comorbidity.
Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.
Results indicate that pemoline is moderately effective in the treatment of ADHD in adults, and given the limited efficacy, tolerability, and concerns of hepatic dysfunction, it should be considered as second-line medication for treating ADHD in adult.
Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder.
The results show that referred and nonreferred adults with attention deficit hyperactivity disorder have a pattern of demographic, psychosocial, psychiatric, and cognitive features that mirrors well-documented findings among children with the disorder.
Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.
The MTA titration protocol validated the efficacy of weekend MPH dosing and established a total daily dose limit of 35 mg of MPH for children weighing less than 25 kg.
Attention deficit disorder ('minimal brain dysfunction') in adults. A replication study of diagnosis and drug treatment.
Pemoline was demonstrably more effective than placebo in a random-assignment, parallel, double-blind trial of placebo and pemoline, a noneuphorigenic psychostimulant drug effective in children with ADD.